Breaking News Instant updates and real-time market news.

CRL

Charles River

$83.48

0.44 (0.53%)

, RHHBY

Roche

$30.56

0.073 (0.24%)

08:05
10/11/16
10/11
08:05
10/11/16
08:05

Charles River announces extension of integrated discovery program with Genentech

Charles River Laboratories International (CRL) announced that it has extended its longstanding integrated drug discovery alliance with Genentech, a member of the Roche Group (RHHBY). Through this alliance, Charles River provides Genentech early discovery services, including medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design, to help identify promising candidates for preclinical development. Charles River and Genentech have engaged in an ongoing program since 2005, with the latest extension providing a three-year continuation. The program began with a single project involving medicinal chemistry, and has evolved over the past 11 years to a multi-disciplinary collaboration drawing on Charles River's researchers in chemistry, biology and pharmacology.

CRL

Charles River

$83.48

0.44 (0.53%)

RHHBY

Roche

$30.56

0.073 (0.24%)

  • 19

    Oct

  • 02

    Nov

  • 06

    Nov

  • 10

    Nov

CRL Charles River
$83.48

0.44 (0.53%)

06/20/16
FBCO
06/20/16
INITIATION
Target $84
FBCO
Neutral
Charles River initiated with a Neutral at Credit Suisse
Target $84.
08/04/16
BARD
08/04/16
NO CHANGE
Target $100
BARD
Outperform
Charles River price target raised to $100 from $92 at Baird
Baird raised its price target on Charles River Labs to $100 from $92 following solid Q2 results. The firm believes the company's outlook is bright and its performance drivers were balanced, noting also that guidance was raised. Baird reiterated its Outperform rating on Charles River shares.
08/18/16
RHCO
08/18/16
NO CHANGE
RHCO
Charles River reported 'strong' results, says SunTrust
SunTrust analyst Sandy Draper says that Charles River reported "strong" results, and he says that the company should benefit from synergies from its acquisition of Wil Research in the next two to three quarters. Draper keeps a Buy rating on the stock.
09/06/16
UBSW
09/06/16
DOWNGRADE
Target $78
UBSW
Sell
Charles River downgraded to Sell from Neutral at UBS
UBS analyst Jonathan Groberg downgraded Charles River Laboratories to Sell saying 2016 looks like a "peak organic growth year" for the company. The analyst sees a "number of risks" to 2017 consensus estimates. He lowered his price target for the shares to $78 from $83.
RHHBY Roche
$30.56

0.073 (0.24%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

HON

Honeywell

$129.88

-0.22 (-0.17%)

08:18
04/28/17
04/28
08:18
04/28/17
08:18
Recommendations
Honeywell analyst commentary  »

Jefferies sees 20%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

DIA

Diamonds Fund ETF

$209.56

0.09 (0.04%)

08:17
04/28/17
04/28
08:17
04/28/17
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$11.51

0.05 (0.44%)

08:17
04/28/17
04/28
08:17
04/28/17
08:17
Earnings
Barclays reports Q1 core EPS 7.2p vs. 5.8p a year ago »

Reports Q1 Group RoTE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALLE

Allegion

$80.62

0.9 (1.13%)

08:17
04/28/17
04/28
08:17
04/28/17
08:17
Recommendations
Allegion analyst commentary  »

Allegion price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

SPY

SPDR S&P 500 ETF Trust

$238.60

0.2 (0.08%)

08:17
04/28/17
04/28
08:17
04/28/17
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMC

UMC

08:17
04/28/17
04/28
08:17
04/28/17
08:17
Periodicals
UMC plans roll out of 22nm process as early as 2018, DigiTimes says »

Chipmaker UMC expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$23.76

-0.11 (-0.46%)

08:17
04/28/17
04/28
08:17
04/28/17
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$81.01

1.07 (1.34%)

08:16
04/28/17
04/28
08:16
04/28/17
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

PowerShares QQQ Trust

$135.75

0.81 (0.60%)

08:16
04/28/17
04/28
08:16
04/28/17
08:16
Technical Analysis
PowerShares QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

08:16
04/28/17
04/28
08:16
04/28/17
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDX

Nasdaq 100 Index

$5,571.28

30.19686 (0.54%)

08:16
04/28/17
04/28
08:16
04/28/17
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$161.98

-2.56 (-1.56%)

08:15
04/28/17
04/28
08:15
04/28/17
08:15
Recommendations
Parker-Hannifin analyst commentary  »

Parker-Hannifin price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
U.S. Q1 GDP preview: »

U.S. Q1 GDP preview:…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

DB

Deutsche Bank

$18.15

-0.69 (-3.66%)

, C

Citi

$59.39

-0.55 (-0.92%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Hot Stocks
Deutsche Bank confirms James von Moltke to succeed Marcus Schenck as CFO »

Deutsche Bank's (DB)…

DB

Deutsche Bank

$18.15

-0.69 (-3.66%)

C

Citi

$59.39

-0.55 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 25

    Jul

WDC

Western Digital

$85.71

1.1 (1.30%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Downgrade
Western Digital rating change  »

Western Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$918.38

9.09 (1.00%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Recommendations
Amazon.com analyst commentary  »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 16

    May

  • 23

    May

LH

LabCorp

$139.68

0.99 (0.71%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Hot Stocks
LabCorp to exclusively offer M3 Checklist for mental illness »

LabCorp and M-3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

ATTO

Atento

$8.85

-0.1 (-1.12%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Earnings
Atento announces prepayment of $27M Brazilian debentures »

Atento made a $26.7M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 11

    May

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts provide an…

TER

Teradyne

$36.35

2.58 (7.64%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Teradyne analyst commentary  »

Teradyne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

  • 21

    Jun

EXPE

Expedia

$136.20

0.45 (0.33%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Expedia analyst commentary  »

Expedia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

LLL

L3 Technologies

$173.94

2.18 (1.27%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
L3 Technologies analyst commentary  »

L3 Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.